When Sarah Park, our producer here at HealthCentral, asked me if I would be interested in writing a post about a trial of lapatinib (trade name Tykerb in the US and Tyverb in Europe) for inflammatory breast cancer (IBC) patients, I jumped at the chance. I’ve been reading about this drug...
-
Important advice, Phyllis
PJ Hamel
Sunday, May 03, 2009 at 08:54 PM
- Font size
- Email This
- Bookmark
- Thank you for your input
- Save
- RSS
- Report Abuse
Love your conclusion, Phyllis - although "medicalese" is very challenging to understand, it's worth making the effort when it's your life that's at stake.
Readers might be interested in our Tykerb FAQS; information on research around lowering the cost of Tykerb by taking fewer doses; and news around Tykerb's FDA approval.
thanks again for the thoughtful read, Phyllis. - PJH